Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

Chiappella A;Martelli M;Angelucci E;Brusamolino E;Evangelista A;Carella AM;Stelitano C;Rossi G;Balzarotti M;Merli F;Gaidano G;Pavone V;Rigacci L;Zaja F;D'Arco A;Cascavilla N;Russo E;Castellino A;Gotti M;Congiu AG;Cabras MG;Tucci A;Agostinelli C;Ciccone G;Pileri SA;Vitolo U;;
the lancet oncology 2017 Vol. 18 pp. -
402
a2017therituximab-dose-dense

Abstract

Fondazione Italiana Linfomi.

Citation

ID: 111365
Ref Key: a2017therituximab-dose-dense
Use this key to autocite in SciMatic or Thesis Manager

References

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
111365
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet

Saymatik Web3.0 Wallet